ENPP1 and hypophosphatemic rickets, autosomal recessive, 2: INZ-701 is a recombinant human ENPP1-Fc fusion protein, which is currently being evaluated in clinical trials to treat patients with generalized arterial calcification of infancy (GACI) and autosomal recessive hypophosphatemic rickets type II (ARHR2), also known as ENPP1 deficiency [21].